Novo Nordisk Healthcare Ag

Novo Nordisk A/s

Anne Charlotte Arentsen

Arne Staby

Janus Krarup

Haleh Ahmadian

Susanne Bang

Thomas Budde Hansen

Are Bogsnes

Daniel E Rasmussen

Per Kaersgaard

The present invention relates to Vitamin K-dependent protein compositions having a very low, or negligible, content of protein contaminants. The present invention also relates to method applicable in the preparation of such Vitamin K-dependent protein compositions. Such methods may either be used alone or in sequential combination with the purpose of reducing the relative content of protein contaminants. The present invention is particularly relevant in the preparation of compositions of coagulation factors selected from Factor X polypeptides (FX/FXa), Factor IX polypeptides (FIX/FIXa), Factor VII polypeptides (FVII/FVIIa), and the anticoagulant Protein C, in particular Factor VII polypeptides.

Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest

The present invention relates to a closed container holding a composition of an activated Factor VII polypeptide in an amount of in the range of 2.5-90 mg per imL volume of the container. The invention also relates to various processes for the preparation of such closed containers, a kit including such containers and a method of using the kit.

Closed container comprising an activated factor VII polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit

Crystals of glucagon-like peptide-1 (GLP-1) and GLP-1 analogues, and processes for preparation of crystals of GLP-1 and GLP-1 analogues.

Crystallization of a GLP-1 analogue

Growing community of inventors

Holte, Denmark

Anne Charlotte Arentsen